The American College of Cardiology (ACC) has issued guidance to help clinicians and patients use health data collected while wearing Apple Watch to effectively track and manage cardiovascular health. ...

The U.S. Food and Drug Administration (FDA) has taken an unprecedented step by authorizing the marketing of four Glas e-cigarettes, including the following pod flavors: Classic Menthol, Fresh Menthol, ...

YOU ARE HERE: Home > Guidelines and Clinical Policy > 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac ...

As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...

Long-term melatonin use for insomnia was associated with a higher hazard of heart failure (HF), an increase in HF hospitalizations and a doubling of all-cause mortality over five years, according to a ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

Spironolactone, an aldosterone blocker, compared with placebo, did not show any significant improvement in terms of heart failure (HF) hospitalizations and cardiovascular death at 24 months in ...

Among patients with severe left ventricular (LV) dysfunction and severe coronary heart disease undergoing complex PCI, elective LV unloading with a microaxial flow pump did not reduce the risk of ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).

Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, ...

A one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by ...